2.30
0.26 (12.75%)
0.26 (12.75%)
Upgrade to Real-Time
Premarket
| Volume | 347 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Eiger BioPharmaceuticals Inc | EIGR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.26 | 12.75% | 2.30 | 04:39:08 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.04 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 10 | 347 | - | 0.96 - 10.0213 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:43:31 | 58 | $ 2.07 | USD |
Period:
Draw Mode:
Eiger BioPharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 101.37M | 44.07M | 36.57M | $ 12.14M | $ -4.32M | -1.01 | -0.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 180.75k | 1.40% |
Eiger BioPharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EIGR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.98 | 2.27 | 1.95 | 2.15 | 838,341 | 0.32 | 16.16% |
| 1 Month | 1.34 | 2.27 | 1.31 | 1.75 | 757,142 | 0.96 | 71.64% |
| 3 Months | 4.26 | 4.62 | 0.96 | 1.52 | 1,154,626 | -1.96 | -46.01% |
| 6 Months | 8.44 | 9.89 | 0.96 | 2.85 | 708,936 | -6.14 | -72.75% |
| 1 Year | 4.55 | 10.0213 | 0.96 | 5.17 | 714,217 | -2.25 | -49.45% |
| 3 Years | 11.78 | 13.99 | 0.96 | 7.10 | 449,876 | -9.48 | -80.48% |
| 5 Years | 8.60 | 18.00 | 0.96 | 7.93 | 328,091 | -6.30 | -73.26% |
Eiger BioPharmaceuticals Description
| Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3. |